Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUXIVIG: Immunoglobulin + Rituximab vs Rituximab Alone in SDNS
NCT03560011Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2019
- Primary completion
- Nov 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in nephrotic syndrome, sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2019; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT03560011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560011.